Login / Signup

Quantitative metric for assessment of pancreatic ductal adenocarcinoma treatment response in T1-weighted gadolinium-enhanced magnetic resonance imaging.

Joy LiauSrinivasan VedanthamHani M BabikerTravis McGlothinDiego R Martin
Published in: Annals of pancreatic cancer (2020)
T1C significantly increases in all phases of CE-MRI in responders to treatment, but does not change in non-responders. T1C correlates with treatment response, can be computed from clinical MRI exams, and may be useful as an additional metric to stratify patients undergoing treatment.
Keyphrases
  • magnetic resonance imaging
  • contrast enhanced
  • patients undergoing
  • diffusion weighted imaging
  • computed tomography
  • magnetic resonance
  • clinical evaluation